Search results for "HECK"
showing 10 items of 682 documents
1630. Orobanche lavandulacea Rchb. in Peruzzi L, Nepi C, Peccenini S (eds) Notulae alla checklist della flora vascolare italiana 9 (1623-1681)
2010
1631. Orobanche schultzii Mutel in Peruzzi L, Nepi C, Peccenini S (eds) Notulae alla checklist della flora vascolare italiana 9 (1623-1681)
2010
1674. Orobanche L. in: Peruzzi L, Nepi C, Peccenini S (Eds): Notulae alla checklist della flora vascolare italiana 9 (1623-1681)
2010
1632-1637. Orobanche lucorum, O. nana, O. pubescens, O. ramosa, O. reticolata, O. teucrii in: Peruzzi L, Nepi C, Peccenini S (Eds): Notulae alla chec…
2010
Orthodontic brackets friction changes after clinical use : a systematic review
2019
Background To evaluate the bracket-wire friction force after clinical use. Material and methods A systematic search of several electronic databases (PubMed, Embase, Web of Science, Scopus, The Cochrane Library, Lilacs and Google Scholar) without limitations regarding publication year or language, was performed. In-vitro studies analyzing the changes in friction force of orthodontic brackets before/after their clinical use were considered. Risk of Bias was assessed with Downs and Black checklist. All methodological features that could interfere in the results were specifically described. Results Seven studies satisfied the inclusion criteria and were included in the review. All 7 studies rep…
MCC1019, a selective inhibitor of the Polo-box domain of Polo-like kinase 1 as novel, potent anticancer candidate
2019
Polo-like kinase (PLK1) has been identified as a potential target for cancer treatment. Although a number of small molecules have been investigated as PLK1 inhibitors, many of which showed limited selectivity. PLK1 harbors a regulatory domain, the Polo box domain (PBD), which has a key regulatory function for kinase activity and substrate recognition. We report on 3-bromomethyl-benzofuran-2-carboxylic acid ethyl ester (designated: MCC1019) as selective PLK1 inhibitor targeting PLK1 PBD. Cytotoxicity and fluorescence polarization-based screening were applied to a library of 1162 drug-like compounds to identify potential inhibitors of PLK1 PBD. The activity of compound MC1019 against the PLK1…
Prognostic Role of Plasma PD-1, PD-L1, pan-BTN3As and BTN3A1 in Patients Affected by Metastatic Gastrointestinal Stromal Tumors: Can Immune Checkpoin…
2021
Gastrointestinal stromal tumors (GISTs) represent 1% of all primary gastrointestinal tumors. Immune surveillance is often overcome by cancer cells due to the activation of immunoregulatory molecules such as programmed death protein (PD-1) and its ligand PD-L1, and butyrophilin sub-family 3A/CD277 receptors (BTN3A). Because several studies demonstrated that tumor PD-1 and PD-L1 expression may have a prominent prognostic function, this investigation aimed to discover if soluble forms of these molecules may be useful in predicting survival of metastatic GIST (mGIST) patients. Through specific ad hoc developed ELISA assays not yet available on the market, the circulating PD-1, PD-L1, BTN3A1, an…
Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone?
2019
International audience; In recent years, multiple strategies for eliciting anti-tumor immunity have been developed in different clinical studies. Currently, immunotherapy was clinically validated as effective treatment option for many tumors such as melanoma, non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC). Some surface receptors of immune cells, called immune checkpoint receptors, may inhibit activity of proinflammatory lymphocytes, following binding with specific ligands. Cancer cells exploit these mechanisms to inactivate tumor-infiltrating lymphocytes (TILs) to escape from immunosurveillance. Among the different tumor-infiltrating immune cell populations, including leu…
A “Lymphocyte MicroRNA Signature” as Predictive Biomarker of Immunotherapy Response and Plasma PD-1/PD-L1 Expression Levels in Patients with Metastat…
2020
Introduction of checkpoint inhibitors resulted in durable responses and improvements in overall survival in advanced RCC patients, but the treatment efficacy is widely variable, and a considerable number of patients are resistant to PD-1/PD-L1 inhibition. This variability of clinical response makes necessary the discovery of predictive biomarkers for patient selection. Previous findings showed that the epigenetic modifications, including an extensive microRNA-mediated regulation of tumor suppressor genes, are key features of RCC. Based on this biological background, we hypothesized that a miRNA expression profile directly identified in the peripheral lymphocytes of the patients before and a…
French Endocrine Society Guidance on endocrine side effects of immunotherapy.
2018
The management of cancer patients has changed due to the considerably more frequent use of immune checkpoint inhibitors (ICPIs). However, the use of ICPI has a risk of side effects, particularly endocrine toxicity. Since the indications for ICPI are constantly expanding due to their efficacy, it is important that endocrinologists and oncologists know how to look for this type of toxicity and how to treat it when it arises. In view of this, the French Endocrine Society initiated the formulation of a consensus document on ICPI-related endocrine toxicity. In this paper, we will introduce data on the general pathophysiology of endocrine toxicity, and we will then outline expert opinion focusing…